Brookfield Corp’s Allogene Therapeutics ALLO Stock Holding History

Brookfield Corp’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-61,494	Closed	-$917K	–	604
2021 Q4	$917K	Buy	+61,494	New	+$1.09M	﹤0.01%	464

Other funds holding ALLO

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

Brookfield Corp's ALLO Position: Q1 2022 in Review

Brookfield Corp sold out of Allogene Therapeutics (ALLO) in Q1 2022, closing a stake of 61,494 shares — an estimated $917K sold.

Brookfield Corp first reported a position in ALLO in Q4 2021 and held it in 1 quarter. The position peaked at $917K in Q4 2021. 180 funds tracked by Wall St. Rank hold ALLO as of Q1 2022.

Brookfield Corp reported no remaining Allogene Therapeutics position as of Q1 2022 after selling out during the quarter.
Brookfield Corp sold 61,494 Allogene Therapeutics shares in Q1 2022, an estimated $917K.
Brookfield Corp first reported a position in Allogene Therapeutics in Q4 2021 and held it in 1 quarter.
Brookfield Corp's Allogene Therapeutics position peaked at $917K in Q4 2021.
180 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2022.

Based on Brookfield Corp's 13F filing for Q1 2022, filed 16 May 2022.